ASCO American Society of Clinical Oncology 2024
- Start Date:
31 May 2024
- End Date:
04 Jun 2024
- Location:
Chicago, IL
- Region:
North America
- Booth #:
10087
Stop by our booth (#10087) to learn how our specialized services can help you advance your oncology drug development with our full spectrum, end-to-end solutions spanning from early drug discovery support and clinical development through market access and commercial strategy:
- Expertise and innovation to help design, plan and execute your early phase oncology clinical trials on time and with quality.
- The latest technology for fast profiling and next generation sequencing of key biomarkers and comprehensive genomic profiling with Oncomine solutions.
- Proven expertise in cell and gene therapy oncology clinical trials, with over 160 immuno-oncology studies and 137 cell and gene therapy trials across tumor types and therapies.
- With rare disease and pediatric expertise across all phases, indications and therapeutic areas — including more than 500 clinical studies — the cross-functional team at our Rare Disease and Pediatrics Center of Excellence delivers innovative, patient-centric solutions to skillfully address the most complex challenges of these trials.
- Laboratory support that combines world-class scientific expertise with industry-leading technologies.
Our specialized capabilities
Visit us at booth #10087 to learn how we can help you meet the complex demands of innovative drug development.
- Recognized as a leader in innovative early phase oncology study designs
- Experts in adaptive trial designs and master protocols
- Proven experience operationalizing adaptive and other innovative trial designs, through our Adaptive Design and Master Protocol Working Group, enables you to unlock better information, faster
End-to-end service provider
Discover how the PPD™ clinical research business of Thermo Fisher Scientific can now provide you expertise in full spectrum, end–to–end solutions spanning from early drug discovery support and clinical development through market access and commercial strategy.
- Providing the latest technology for fast profiling and next generation sequencing of key biomarkers and comprehensive genomic profiling with Oncomine solutions.
- Evidera, our dedicated peri- and post-approval business, brings over 35 years of scientific rigor and operational expertise, in translating favorable pre-approval clinical trial results into success in the real world.
- Laboratory support that combines world–class scientific expertise with industry-leading technologies.
Proven expertise in cell and gene therapy oncology clinical trials
When it comes to cell and gene therapy (CGT) clinical trials, you need to put your trust in expertise and experience. Our clinical research team has spent decades on the development and management of CGT trials, including 160 immuno-oncology studies and 137 cell and gene therapy trials across tumor types and therapies.
Over the years, we’ve supported more than 33,000 patients, and we offer comprehensive laboratory support for cell and gene therapies, including
CAR-T.
Immuno-oncology center of excellence
With our Immuno-Oncology Center of Excellence, we enable drug developers to pursue their therapies with confidence, providing a knowledge base on the competitive environment, efficient adaptive designs and dynamic regulatory landscape that surround these rapidly evolving immunotherapies.
Our experience spans more than a decade and includes over 160 trials on:
- Adoptive cell therapies
- Cancer vaccines
- Checkpoint inhibitors
- Cytokines
- Immune modulators
- Monoclonal antibodies
Our Cell and Gene Institute offers cross-functional expertise that spans diverse technologies and delivery mechanisms, including cell, gene, gene-modified cell and advanced tissue technologies. It also offers cross-functional expertise with oncology and hematology physicians conversant in CAR-T with investigators and key opinion leaders at the top of their field.